Cabaletta Bio (CABA) Expected to Release Earnings on Monday

Key Points

• Cabaletta Bio is expected to report Q3 2026 results before the market opens on Monday, November 9. Analysts forecast a loss of $0.33 per share and revenue of $1.67 million; the earnings call is scheduled for November 13 at 9:30 a.m. ET.
• The company reported a Q2 loss of $0.34 per share, beating consensus estimates by $0.03. Analysts expect full-year and next-year losses of $1.34 and $1.13 per share, respectively.
• CABA shares opened at $1.51, near their 52-week low of $1.32 and below their 50-day and 200-day moving averages. Despite mixed ratings, analysts maintain a “Moderate Buy” consensus with a $15.60 target price.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) is expected to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to post earnings of ($0.33) per share and revenue of $1.67 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. On average, analysts expect Cabaletta Bio to post ($1.34) EPS for the current fiscal year and ($1.13) EPS for the next fiscal year.

Cabaletta Bio Stock Performance

Shares of CABA stock opened at $1.51 on Monday. The firm has a fifty day moving average of $2.30 and a 200-day moving average of $2.84. The stock has a market cap of $256.01 million, a price-to-earnings ratio of -0.96 and a beta of 3.56. Cabaletta Bio has a 52-week low of $1.32 and a 52-week high of $4.23.

Analyst Ratings Changes

Several brokerages recently commented on CABA. William Blair raised Cabaletta Bio to a "strong-buy" rating in a research note on Wednesday, September 23rd. Wells Fargo & Company lowered their target price on shares of Cabaletta Bio from $4.00 to $3.00 and set an "equal weight" rating on the stock in a report on Friday, August 14th. TD Cowen raised shares of Cabaletta Bio to a "strong-buy" rating in a report on Monday, August 24th. Wall Street Zen lowered shares of Cabaletta Bio from a "sell" rating to a "strong sell" rating in a research report on Saturday, October 17th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Cabaletta Bio in a report on Tuesday, September 1st. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $15.60.

About Cabaletta Bio

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company's approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.